Skip to main content
HLS Therapeutics Inc. logo

HLS Therapeutics Inc. — Investor Relations & Filings

Ticker · HLS ISIN · US40390B3078 LEI · 549300QKXFY1J71L2D68 TSX Wholesale and retail trade
Open in API
Filings indexed 364 across all filing types
Latest filing 2023-05-17 Regulatory Filings
Country CA Canada
Listing TSX HLS

About HLS Therapeutics Inc.

https://hlstherapeutics.com/

HLS Therapeutics Inc. is a specialty pharmaceutical company focused on the acquisition and commercialization of branded medicines across North America. The company targets products that address unmet needs, primarily in the treatment of psychiatric disorders and cardiovascular disease/risk reduction. Its commercial-stage portfolio includes CLOZARIL® (clozapine) for psychiatric disorders and VASCEPA® (icosapent ethyl) for cardiovascular risk reduction. HLS also commercializes NILEMDO® (bempedoic acid) and NEXLIZET® (bempedoic acid/ezetimibe combination) for the reduction of LDL-cholesterol in patients at risk of cardiovascular disease. HLS ensures reliable market access to these essential therapies by sourcing products directly from originators and best-in-class manufacturing partners.

Recent filings

Filing Released Lang Actions
Material change report - English.pdf
Regulatory Filings
2023-05-17 English
52-109F2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings
2023-05-11 English
Interim MD&A - English.pdf
Regulatory Filings
2023-05-11 English
News release - English.pdf
Regulatory Filings
2023-05-11 English
News release - English.pdf
Call Transcript Classification · 80% confidence The document is an announcement from HLS Therapeutics about an upcoming conference call to discuss Q1 Fiscal 2023 financial results. It includes details about the date, time, webcast link, and replay information. There is no actual financial data or detailed report content included. The document is short (2502 characters) and serves to notify investors about the event rather than presenting the financial results themselves. According to the rules, such announcements about upcoming earnings calls are classified as Call Transcripts (CT) only if they contain the full transcript, which this does not. It is an announcement of the call, not the transcript or the earnings release itself. The best fit is a Call Transcript (CT) category because it relates to the conference call event, but since it is only an announcement, it might be considered a Regulatory Filing (RNS). However, given the specific nature of the announcement about the earnings call, the classification as Call Transcript (CT) is appropriate with moderate confidence.
2023-05-03 English
News release - English.pdf
Investor Presentation Classification · 70% confidence The document is a press release announcing that HLS Therapeutics will present at the 2023 Bloom Burton & Co. Healthcare Investor Conference. It includes details about the presentation date, time, webcast link, and background information about the company and the conference. There is no financial data, no detailed report, no voting results, no management changes, no legal proceedings, or other regulatory filings. The document is an announcement of an upcoming investor presentation event rather than the presentation itself or a financial report. Therefore, the most appropriate classification is Investor Presentation (IP) as it relates to a presentation for investors focusing on financials, strategy, and market position, even though the actual presentation content is not included here, the announcement is about the presentation event itself. Given the document length is short and it is an announcement, but the content is about an investor presentation event, the best fit is IP with moderate confidence.
2023-04-21 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.